Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
![UCB’s anti-epileptic drug VIMPAT[®] (lacosamide) receives EU CHMP positive opinion for primary generalised tonic-clonic seizures](/_up/ucb_com_presscenter/images/presscenter_teaser_10.jpg?300)
Twitter Feed
-
#ECTS2020 starts today! We are excited to be participating in this years’ virtual congress where we will be partnering with bone specialists across the world to discuss developments in #osteoporosis and #fragilityfracture care! Don’t forget to register: h
— UCB News (@ucb_news) 22.10.2020 -
At this year’s digital #ECTS2020 Congress, we are delighted to be working with Professor Thierry Thomas. Want to know more about why he thinks this a congress not to be missed? Listen to this short clip! Remember to register for the congress here: https:
— UCB News (@ucb_news) 21.10.2020 -
Partnering with the IOF, the University of Oxford and Amgen we have a goal to help reduce global hip & vertebral fractures by 25% by 2025. So, on WOD 2020 we’re proud to share some of the progress made to date. https://t.co/nISWY54WuM
— UCB News (@ucb_news) 20.10.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
